Clinica    Scrip    Scrip Regulatory Affairs    Scrip Clinical Research    Animal Pharm   
Email ID
Password
Forgotten password?
Sign me in automatically next time
Home
Market Sector
Business
Policy & Regulation
Regions
IVDs
|
Imaging & IT
|
Cardiovascular
|
Orthopaedics
|
Surgical & Wound care
|
Cellular & Genetic
|
Neurological
|
Other
|
clinica
Market Sector - Cardiovascular
Stryker’s Wingspan clipped by study showing higher stroke risk versus drug therapy
08 September 2011
Stryker’s brain stent system Wingspan has been dealt a blow after a study found that the device, when used to treat clogged arteries in the brain, was linked with an increased risk of stroke and death compared with drug therapy alone. The findings ...
Medtronic's Resolute DES beats Boston's Taxus in Japanese study
26 July 2011
Medtronic's new-generation drug-eluting stent Resolute has beaten Boston Scientific's Taxus DES, a rival product and one of the established brands in the DES market, in a Japanese clinical study. The positive results should help Medtronic obtain ...
St Jude picks up Medtronic's GPO slack with new contract
26 July 2011
St Jude Medical has taken over a group purchasing organisation (GPO) contract previously held by rival Medtronic. The news comes months after Medtronic cancelled several large GPO contracts, leading to suggestions that other big players might also ...
FDA panel nod for Sapien a positive – but Edwards mustn't get ahead of itself, says analyst
21 July 2011
A US FDA advisory panel yesterday voted for the approval of Edwards Lifesciences' Sapien heart valve system for use on inoperable patients with severe aortic stenosis. The recommendation was not unexpected, taking into consideration that FDA ...
Edwards' Sapien TAVI device closer to US approval with positive FDA report
19 July 2011
Edwards Lifesciences looks ever closer to achieving its goal of launching its Sapien heart valve system in the US this year, after FDA reviewers issued a positive report on the safety and efficacy data of the device. The report should work in ...
 
Lumedx, Mennen Medical in cath lab partnership
02 April 2009
Cardiovascular imaging firm Lumedx is set to team up with Israeli cardiac catheterisation and electrophysiology specialist Mennen Medical in a bid to provide customers with a more integrated cath lab. The deal will combine Lumedx’s CardioStar ...
 
The future of cardiac monitoring is wireless 14 October 2009

Patients requiring long-term cardiac monitoring have been using the same types of devices for nearly 50 years – but a new wave of wireless technology looks set to change this. Madeleine Armstrong spoke to Borge Bogaard, CEO of Curvus, and Julien ...

Michael Mussallem: how innovations will spur cardio industry 15 September 2009

It is not yet apparent what the next game-changing technology in the cardiovascular market will be, says Edwards Lifesciences ’ CEO Michael Mussallem. “Currently people are projecting moderate growth for the market. What I would suggest is ...

ESC 2009: New biomarkers and more sensitive tests enable earlier diagnosis of heart attacks 03 September 2009

More sensitive blood tests and combinations of biomarkers should allow more accurate and rapid diagnosis of heart attacks. So said Christian Müller of University Hospital Basel, Switzerland, in a presentation on August 31 at the annual meeting of ...

 
A 1 adenosine receptor agonists and their potential therapeutic applications
01 December 2008
Background: The challenges in developing any A 1 adenosine receptor (A 1 -AdoR) agonist involve having the desired effect on target tissue while avoiding side effects due to activation of A 1 -AdoR on other tissues. A 1 -AdoR de-sensitization ...
Plasma levels of osteopontin before and 24 h after percutaneous coronary intervention
01 December 2008
Objective: Previous studies demonstrated that osteopontin (OPN) was increased after vascular injury, such as atherosclerosis and restenosis following angioplasty. We sought to determine the effects of percutaneous coronary intervention (PCI) on ...
Autophagy: a target for therapeutic interventions in myocardial pathophysiology
01 December 2008
Background: Autophagy is a major degradative and highly conserved process in eukaryotic cells that is activated by stress signals. This self-cannibalisation is activated as a response to changing environmental conditions, cellular remodelling during ...
 
 
COMPANY/ORGANISATION


Loading COMPANY/ORGANISATION ....
 
CONDITION


Loading CONDITION ....
 
GEOGRAPHY


Loading GEOGRAPHY ....
 
 
© 2012 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36
Home
Market Sector
Business
Policy & Regulation
Regions
Terms & Conditions
Privacy Policy
Sitemap
About Us
Advertise
Subscribe
Clinica
Scrip
Scrip Regulatory Affairs
Scrip Clinical Research
Animal Pharm